IL161231A0 - Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease - Google Patents

Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Info

Publication number
IL161231A0
IL161231A0 IL16123102A IL16123102A IL161231A0 IL 161231 A0 IL161231 A0 IL 161231A0 IL 16123102 A IL16123102 A IL 16123102A IL 16123102 A IL16123102 A IL 16123102A IL 161231 A0 IL161231 A0 IL 161231A0
Authority
IL
Israel
Prior art keywords
inhibitors
heart disease
myocardial dysfunction
structural heart
treat myocardial
Prior art date
Application number
IL16123102A
Other languages
English (en)
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of IL161231A0 publication Critical patent/IL161231A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
IL16123102A 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease IL161231A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32657601P 2001-10-01 2001-10-01
US32801001P 2001-10-08 2001-10-08
PCT/US2002/031496 WO2003029428A2 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Publications (1)

Publication Number Publication Date
IL161231A0 true IL161231A0 (en) 2004-09-27

Family

ID=26985461

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16123102A IL161231A0 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Country Status (14)

Country Link
US (2) US7320959B2 (pt)
EP (1) EP1439849A4 (pt)
JP (1) JP2005504829A (pt)
KR (1) KR20040045041A (pt)
CN (1) CN1599622A (pt)
AU (1) AU2002341938B2 (pt)
BR (1) BR0213043A (pt)
CA (1) CA2462443A1 (pt)
IL (1) IL161231A0 (pt)
MX (1) MXPA04003040A (pt)
NO (1) NO20041331L (pt)
NZ (1) NZ532327A (pt)
PL (1) PL369104A1 (pt)
WO (1) WO2003029428A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006049215A1 (ja) * 2004-11-02 2008-05-29 大日本住友製薬株式会社 自己免疫疾患を治療するための併用薬
ES2431578T3 (es) * 2008-04-09 2013-11-27 B.R.A.H.M.S Gmbh Proendotelina-1 para la predicción del consumo de oxígeno máximo disminuido
US8841423B2 (en) * 2008-04-28 2014-09-23 University Of Iowa Research Foundation Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
US20090275514A1 (en) * 2008-05-01 2009-11-05 Anderson Mark E Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation
US9506032B2 (en) * 2009-05-22 2016-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered biological pacemakers
US8440656B2 (en) * 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
AU2014225889B2 (en) 2013-03-06 2018-12-06 The Johns Hopkins University CaMKII inhibitors and uses thereof
DE102014201651A1 (de) * 2014-01-30 2015-07-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen
AU2015311730A1 (en) 2014-09-05 2017-04-20 Allosteros Therapeutics, Inc Camkii inhibitors and uses thereof
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
CN112972447B (zh) * 2021-03-02 2022-09-23 扬州大学附属医院 CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (pt) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
EP0966274B1 (en) * 1997-01-31 2002-06-12 The Board Of Trustees Of The Leland Stanford Junior University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
JP2963986B2 (ja) * 1997-11-19 1999-10-18 工業技術院長 カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤

Also Published As

Publication number Publication date
NZ532327A (en) 2005-10-28
US20040266675A1 (en) 2004-12-30
AU2002341938B2 (en) 2007-08-30
KR20040045041A (ko) 2004-05-31
BR0213043A (pt) 2004-10-05
JP2005504829A (ja) 2005-02-17
US7320959B2 (en) 2008-01-22
EP1439849A4 (en) 2005-09-28
PL369104A1 (en) 2005-04-18
NO20041331D0 (no) 2004-03-31
CN1599622A (zh) 2005-03-23
MXPA04003040A (es) 2004-07-15
WO2003029428A8 (en) 2004-04-22
US20090011989A1 (en) 2009-01-08
EP1439849A2 (en) 2004-07-28
WO2003029428A3 (en) 2003-10-30
NO20041331L (no) 2004-05-28
WO2003029428A2 (en) 2003-04-10
US7632815B2 (en) 2009-12-15
CA2462443A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
IL161231A0 (en) Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease
AU2002305756A8 (en) Use of nf-kappa-b inhibitors to treat dry eye disorders
TW200607803A (en) Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
EP1689393A4 (en) PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS
IL148719A0 (en) Kinase inhibitors as therapeutic agents
AU5523701A (en) Methods of using growth factors for treating heart disease
ZA200704476B (en) Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
HUP0201009A2 (en) Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
IL147455A0 (en) Purine derivative inhibitors of tyrosine protein kinase syk
NO20015112L (no) Anvendelse av glykosylceramidsynteseinhibitorer ved terapi
IL160928A0 (en) Use of histamine to treat liver disease
IL144507A0 (en) Use of glycogen phosphorylase inhibitors to inhibit tumor growth
EP1267888A4 (en) USE OF LOW-DOSEED BISPHOSPHONATES FOR PREVENTING THE CALIBRATION OF HEART AND ARTERIES
HRP20030874A2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
PL373759A1 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
GB0023915D0 (en) Treatment of neuroinflammatory disease
AU2002307100A1 (en) Use of tumor necrosis factor inhibitors to treat cardiovascular disease
NO20033541D0 (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases
EP1472282A4 (en) USE OF CALMODULIN TO PROMOTE BONE REGENERATION
IL149561A0 (en) Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
GB0012487D0 (en) Use of metal compounds to treat gastrointestinal infections
SI1176981T1 (sl) Zdravljenje avtoimunskih bolezni z antagonisti, ki se vezejo na B celicne povrsinske markerje
IL155814A0 (en) Treatment of sexual dysfunction using bombesin antagonist
HRPK20000421B1 (en) Cytokine related treatments of disease